Extraction Outcomes of Implantable Cardioverter-Defibrillator Leads Vary by Manufacturer and Model Family.

AIMS: Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes.

METHODS: The study cohort included all consecutive patients with ICD who underwent TLE between 2013-2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry.

RESULTS: A total of 885 ICD leads, (median implant duration 8 yrs) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age >10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age >15 years and longer lead extraction time, and predictors of all-cause mortality within 30-days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association function class.

CONCLUSION: Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal.